Immune Cell Subgroups in Covid 19 Patients

NCT04531319 | Completed

• 1 other identifier: Covid Cell
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

COVID-19, spreading rapidly all over the world, causes serious morbidity and mortality. In severe COVID-19 infections, after pulmonary inflammation, cardiovascular organ failure, cytokine storm, hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and isolated organ failure turns into multi-organ failure. It is noteworthy that it causes lymphopenia in patients. In studies conducted, the effects of Covid-19 on the immune system were evaluated with limited parameters. In addition, no study evaluating the effect of this disease on the immune system has been published in our country.

Conditions

Covid19

Keywords

T helper cell; T cytotoxic cell; Monocyte; NK cell

Outcome Measures

Primary Outcomes (1)

• T cell subtype ratios

  T helper, NK cell and T cytotoxic cell ratio

  1 month

Secondary Outcomes (1)

• Monocyte ratio

  1 month

Study Arms (2)

Case Group

Covid 19 (+) patients

Diagnostic Test: Flow cytometric analysis

Control Group

Healthy volunteers

Diagnostic Test: Flow cytometric analysis

Interventions

Flow cytometric analysis DIAGNOSTIC_TEST

Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes

Case Group; Control Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who admitted to the emergency department with the complaint of respiratory failure, lymphopenia in blood tests and Covid 19 (+) in the PCR tests are case group. Also healty volunteers who don't have complaint of respiratory failure, lymphopenia in blood tests and Covid 19 (-) in the PCR tests are control group.

You may qualify if:

• Patients with Covid 19 PCR (+) results

You may not qualify if:

• Cancer Patients
• Patients with known immunodeficiency
• Pregnancy

Sponsors & Collaborators

• Istanbul Training and Research Hospital: lead

Study Sites (1)

Istanbul Training and Reseach Hospital

Istanbul, 34098, Turkey (Türkiye)

Location

Related Publications (3)

• Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020 Aug;20(8):911-919. doi: 10.1016/S1473-3099(20)30287-5. Epub 2020 Apr 27.

  PMID: 32353347 BACKGROUND

• Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020 Jun;215:108448. doi: 10.1016/j.clim.2020.108448. Epub 2020 Apr 27.

  PMID: 32353634 BACKGROUND

• Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020 Jul;83:102437. doi: 10.1016/j.bcmd.2020.102437. Epub 2020 Apr 13.

  PMID: 32325421 BACKGROUND

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Ufuk Oguz Idiz, Assoc. Prof

  Istanbul Training and Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof.

Study Record Dates

• First Submitted: August 27, 2020
• First Posted: August 28, 2020
• Study Start: August 15, 2020
• Primary Completion: October 1, 2020
• Study Completion: October 1, 2020
• Last Updated: January 12, 2021

Record last verified: 2021-01

Locations

TU (1)